Skip to main content Skip to navigation
We care about your privacy. Read about your rights and how we protect your data. Get Details

Pediatric Oncologist Gregory Reaman, MD, Honored with ASPHO Distinguished Career Award

April 29, 2013

Washington, DC— Gregory H. Reaman, MD, Associate Director of the Food and Drug Administration’s Office of Hematology and Oncology Products, and a Children’s National Medical Center Oncology faculty member, has received the 2013 Distinguished Career Award from the American Society of Pediatric Hematology/Oncology (ASPHO).

“I congratulate Dr. Reaman on this well-deserved honor,” said Mark L. Batshaw, MD, Executive Vice President and Chief Academic Officer, Children’s National; Director, Children’s Research Institute; and Chairman, Department of Pediatrics, George Washington University. “It has been my privilege to work with him for many years, including during his years of leadership of the Oncology program here at Children’s National. Dr. Reaman has played a unique role in advancing understanding of pediatric cancer, helping to save and improve many children’s lives through his extensive research, his advocacy for federal funding for pediatric cancer research, and his outstanding record of volunteer service to the profession, which extends internationally.”

The award was presented April 26 at ASPHO’s annual meeting in Miami. The Distinguished Career Award is presented annually to a senior physician or other professional who during his or her career has had a major impact on the care and research of children with cancer or blood disorders and/or has made an impact on the subspecialty through a combination of research, education, patient care, and advocacy.

ASPHO noted that Dr. Reaman “is overwhelmingly admired and praised by colleagues for his leadership as the inaugural chair of the Children’s Oncology Group (COG),” a position he held for 10 years. He guided COG to become the leading research organization worldwide for children with cancer, building an infrastructure for clinical trials across more than 200 participating institutions and establishing a large pediatric tumor bank. During Dr. Reaman’s term at the helm of COG, more than 300 studies were completed, more than 100,000 children were enrolled in research studies, and significant advances occurred in treating acute lymphoblastic leukemia, acute myeloid leukemia, brain tumors, and neuroblastoma.

Dr. Reaman is executive director emeritus and senior attending physician at the Center for Cancer and Blood Disorders, with the Division of Hematology and Oncology at Children’s National, where he has been an attending physician since 1979, following a year as an investigator at the National Cancer Institute. He has published more than 300 peer-reviewed manuscripts, reviews, books, and chapters. He has received research funding from the National Cancer Institute, the Leukemia and Lymphoma Society, and private foundations.

Contact: Emily Hartman or Paula Darte, 202-476-4500

About Children's National Health System

Children’s National Health System, based in Washington, D.C., has served the nation’s children since 1870. Children’s National is one of the nation’s Top 5 pediatric hospitals and, for a second straight year, is ranked No. 1 in newborn care, as well as ranked in all specialties evaluated by U.S. News & World Report. It has been designated two times as a Magnet® hospital, a designation given to hospitals that demonstrate the highest standards of nursing and patient care delivery. This pediatric academic health system offers expert care through a convenient, community-based primary care network and specialty outpatient centers in the D.C. Metropolitan area, including the Maryland suburbs and Northern Virginia. Home to the Children’s Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National is the seventh-highest NIH-funded pediatric institution in the nation. Children’s National is recognized for its expertise and innovation in pediatric care and as a strong voice for children through advocacy at the local, regional and national levels. 

For more information, follow us on Facebook and Twitter.

Latest Tweets